GlassScriptPhysician profile
Tye Frank Johnson
NPI 1467955526
$1,778.25
in general payments reported to CMS, 2019-2025
28 companies · $69.10 in 2025
The $69.10 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $779 · 2022: $685 · 2023: $83.67 · 2024: $162 · 2025: $69.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $185.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $151.52 | 2021-2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.65 | 2021-2022 | |
| Mylan Specialty L.P. | $90.86 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $82.94 | 2021 | |
| Novo Nordisk INC | $74.89 | 2021 | |
| Nestle Healthcare Nutrition INC. | $74.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $74.52 | 2021-2022 | |
| Lilly USA, LLC | $72.01 | 2021-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $70.43 | 2021-2022 | |
| Glaxosmithkline, LLC. | $46.02 | 2021-2025 | Arexvy, Shingrix |
| Amgen INC. | $44.98 | 2021-2024 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $43.05 | 2021-2024 | Gvoke Hypopen |
| Pfizer INC. | $40.46 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $29.37 | 2024 | Myosure Tissue Removal Device |
| Ucb, INC. | $27.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.98 | 2022 | |
| Dexcom, INC. | $26.49 | 2021-2022 | |
| Amarin Pharma, INC. | $24.69 | 2022 | |
| Mannkind Corporation | $18.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.86 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.76 | 2022 | |
| Daiichi Sankyo INC. | $13.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.60 | 2021 | |
| Upsher-Smith Laboratories LLC | $13.16 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.23 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tye Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.